Lupin launches generic Silodosin Capsules 4mg and 8mg

Deepthi | Myequity news | Date : 04-12-2018 16:15:00 IST

Lupin launched Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Silodosin Capsules 4mg and 8mg; is the generic equivalent of Allergan’s Rapaflo®. An alpha-1 adrenergic receptor antagonist, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Rapaflo® had annual sales of $198.5 million in the US (IQVIA MAT September 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


More from Myequity